SEC Company Response from Riot Platforms, Inc. (RIOT) (CIK 0001167419) (RIOT) — Dec 19, 2008
Riot Platforms, Inc. (RIOT) (CIK 0001167419)
Date: Dec. 19, 2008 · CIK: 0001167419 · Accession: 0001079973-08-001151
AI Filing Summary & Sentiment
File numbers found in text: 001-33675
Referenced dates: December 15, 2008
Letter
Re: AspenBio Pharma, Inc. ("AspenBio") Form 10-KSB for the Period Ended December 31, Form 10-Q for the Quarterly Period Ended September 30, 2008
Correspondence
AspenBio Pharma, Inc. South Perry Street Castle Rock, CO 80104
December 19, 2008
Via Edgar
Kei Ino, Staff Accountant United States Securities and Exchange Commission Division of Corporate Finance 100 F. Street, NE
Mail Stop 6010 Washington, D.C. 20549-7010
File No. 001-33675
Ms. Ino:
We are in receipt of the Commission’s comment letter dated December 15, 2008 regarding AspenBio’s most recent Form 10-KSB and Form 10-Q, which requests that AspenBio provide a response to those comments within ten business days. We are currently working with our auditors and legal counsel to address the Commission’s comments and preparing a response. As you discussed with our legal counsel yesterday, December 18, 2008, AspenBio plans to submit a response to the Commission by January 15, 2009. Please advise us if the Commission has any objection to the time frame in which AspenBio plans to respond to the Commission’s comments. I can be reached at 303-794-2000. Alternatively our legal counsel Theresa M. Mehringer, Esq. can be reached at 303-796-2626.
Thank you for your cooperation with this matter.
Sincerely yours,
ASPENBIO PHARMA, INC.
Show Raw Text
CORRESP
1
filename1.htm
Correspondence
AspenBio Pharma, Inc.
1585
South Perry Street
Castle Rock, CO 80104
December 19, 2008
Via Edgar
Kei Ino, Staff Accountant
United
States Securities and Exchange Commission
Division of Corporate Finance
100 F. Street, NE
Mail Stop 6010
Washington, D.C. 20549-7010
Re:
AspenBio
Pharma, Inc. ("AspenBio")
Form 10-KSB for the Period Ended December 31,
2007
Form 10-Q for the Quarterly Period Ended September 30, 2008
File No. 001-33675
Ms. Ino:
We
are in receipt of the Commission’s comment letter dated December 15, 2008 regarding
AspenBio’s most recent Form 10-KSB and Form 10-Q, which requests that AspenBio
provide a response to those comments within ten business days. We are currently working
with our auditors and legal counsel to address the Commission’s comments and
preparing a response. As you discussed with our legal counsel yesterday, December 18,
2008, AspenBio plans to submit a response to the Commission by January 15, 2009. Please
advise us if the Commission has any objection to the time frame in which AspenBio plans to
respond to the Commission’s comments. I can be reached at 303-794-2000. Alternatively
our legal counsel Theresa M. Mehringer, Esq. can be reached at 303-796-2626.
Thank
you for your cooperation with this matter.
Sincerely yours,
ASPENBIO PHARMA, INC.
/s/ Jeff McGonegal
Chief Financial Officer